| 2020 | A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis | 문영철 | Article |
| 2011 | Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers | 문영철 | Meeting Abstract |
| 2023 | Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) | 이경은 | Article |
| 2020 | Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study | 곽혜선; 한혜원; 문진영 | Article |
| 2016 | Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study | 문영철 | Article |
| 2009 | Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). | 문영철 | Meeting Abstract |
| 2010 | Intensified 1st Cycle Rituximab (R) Plus 8(th) Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20(+) Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis. | 문영철 | Meeting Abstract |
| 2023 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 문영철 | Article |
| 2011 | Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation | 문영철 | Meeting Abstract |
| 2023 | Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) | 문영철 | Article |
| 2020 | Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study) | 문영철 | Article |
| 2012 | Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement. | 문영철 | Meeting Abstract |
| 2018 | Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study | 곽혜선 | Article |
| 2012 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. | 문영철 | Meeting Abstract |
| 2011 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis | 문영철 | Meeting Abstract |
| 2021 | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | 문영철 | Review |
| 2007 | The clinical outcomes of autologous stem cell transplantation in peripheral T cell lymphoma: From retrospective Multicenter study in Korea. | 문영철 | Meeting Abstract |
| 2018 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 문영철 | Article |
| 2020 | The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) | 문영철 | Article |
| 2020 | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) | 이경은 | Article |
| 2010 | VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma | 정화순; 문영철 | Meeting Abstract |
